Abstract: The invention relates to nanodevices for the controlled release of substances which comprises a support coated in oligosaccharides, wherein said oligosaccharides comprise at least 3 units of monosaccharides, and wherein at least one of the monosaccharides is galactose. These nanodevices release their load specifically in senescent cells. The invention also encompasses the method of obtainment and its uses.

Abstract: The invention relates to a method to predict the response to treatment with radiotherapy combined with cisplatin-based chemotherapy in patients with cancer, preferably non-microcytic lung cancer, wherein said method is based on the detection of the presence of methylation in the IGFBP-3 gene. The present invention also relates to an in vitro method to design a customised treatment for an individual with said disease. The method of the invention may be quantitative or semi-quantitative. The present invention also relates to a probe designed for the quantitative detection of the methylation of the IGFBP-3 gene, to a kit that comprises it and to the use of the kit to predict the response of a subject to the aforementioned treatment.

Abstract: This invention relates to a compound that induces or activates telomerase activity based on the nucleotide sequence of the GSE 24.2 fragment of dyskerin or the protein or peptide sequence encoded by said nucleotide sequence. Another part of the invention relates to vectors that comprise said sequence and cells transformed thereby, and pharmaceutical compositions that contain all these elements. These compositions may be used in the treatment of diseases from the following group: ageing or acceleration of ageing, neurodegenerative diseases and dyskeratosis congenita.

Abstract: This invention relates to a polypeptide which comprises the fragment SEQ ID No. 2 of peptide GSE24.2 (SEQ ID No. 1) and can reduce the production of free radicals and/or damage to the DNA structure of a cell, optionally comprising nuclear localisation sequences. The invention also relates to a polynucleotide and to a vector, which comprise sequences coding for said polypeptide, and to a pharmaceutical composition comprising said polypeptide, polynucleotide and/or vector. The invention further relates to the applications of the polypeptide such as the use thereof for treating and/or preventing diseases caused by an increase in oxidative stress and/or damage to cellular DNA, such as ataxia-telangiectasia or dyskeratosis congenita, or the use thereof in tissue engineering and cell culture for increasing the viability of same.

Abstract: The invention relates to a method to predict the response to treatment with radiotherapy combined with cisplatin-based chemotherapy in patients with cancer, preferably non-microcytic lung cancer, wherein said method is based on the detection of the presence of methylation in the IGFBP-3 gene. The present invention also relates to an in vitro method to design a customised treatment for an individual with said disease. The method of the invention may be quantitative or semi-quantitative. The present invention also relates to a probe designed for the quantitative detection of the methylation of the IGFBP-3 gene, to a kit that comprises it and to the use of the kit to predict the response of a subject to the aforementioned treatment.

Abstract: The invention relates to biodegradable PLGA bionanoparticles encapsulating the GSE24-2 peptide with telomerase activity and to pharmaceutical, cosmetic and biotechnological compositions comprising same. The pharmaceutical compositions are useful for treating diseases presenting a telomerase deficiency, such as dyskeratosis congenita, and diseases presenting ageing characteristics, such as Werner syndrome, Rothmund Thompson syndrome, and other diseases where there is DNA damage such as ataxia telangiectasia. The invention likewise relates to the method for producing said bionanoparticles by means of a w/o/w double emulsion technique.

Abstract: This invention relates to a compound that induces or activates telomerase activity based on the nucleotide sequence of the GSE 24.2 fragment of dyskerin or the protein or peptide sequence encoded by said nucleotide sequence. Another part of the invention relates to vectors that comprise said sequence and cells transformed thereby, and pharmaceutical compositions that contain all these elements. These compositions may be used in the treatment of diseases from the following group: ageing or acceleration of ageing, neurodegenerative diseases and dyskeratosis congenita.

Abstract: The invention relates to nanodevices for the controlled release of substances which comprises a support coated in oligosaccharides, wherein said oligosaccharides comprise at least 3 units of monosaccharides, and wherein at least one of the monosaccharides is galactose. These nanodevices release their load specifically in senescent cells. The invention also encompasses the method of obtainment and its uses.

Abstract: This invention relates to a compound that induces or activates telomerase activity based on the nucleotide sequence of the GSE 24.2 fragment of dyskerin or the protein or peptide sequence encoded by said nucleotide sequence. Another part of the invention relates to vectors that comprise said sequence and cells transformed thereby, and pharmaceutical compositions that contain all these elements. These compositions may be used in the treatment of diseases from the following group: ageing or acceleration of ageing, neurodegenerative diseases and dyskeratosis congenita.

Abstract: This invention describes the use of an inductor or activator compound GSE24.2 for producing a medicament or pharmaceutical composition for treating a preferably human illness or pathological situation caused by a senescence process. Said pharmaceutical composition can be useful for a treatment of tissue regeneration, for example of epithelial tissues or haematopoietic cells, and also for the immortalisation of eukaryote cells for use of same in biotechnological research or processes.

Abstract: This invention relates to a compound that induces or activates telomerase activity based on the nucleotide sequence of the GSE 24.2 fragment of dyskerin or the protein or peptide sequence encoded by said nucleotide sequence. Another part of the invention relates to vectors that comprise said sequence and cells transformed thereby, and pharmaceutical compositions that contain all these elements. These compositions may be used in the treatment of diseases from the following group: ageing or acceleration of ageing, neurodegenerative diseases and dyskeratosis congenita.